[1]马俊丽,曲文闻,胡晓梅.含砷中药复方青黄散治疗骨髓增生异常综合征的克隆选择性与砷体内效应的相关性研究[J].中国中医药信息杂志,2013,20(6):8-10.[doi:10.3969/j.issn.1005-5304.2013.06.004]
 [J].zhongguo zhongyiyao xinxi zazhi,2013,20(6):8-10.[doi:10.3969/j.issn.1005-5304.2013.06.004]
点击复制

含砷中药复方青黄散治疗骨髓增生异常综合征的克隆选择性与砷体内效应的相关性研究

参考文献/References:

[1] 胡晓梅,麻柔,许勇钢,等.青黄散在恶性血液病治疗中的应用[J].国际中医中药杂志,2011,33(6):568-570.

[2] 胡晓梅,刘锋,麻柔,等.周霭祥运用青黄散治疗白血病的经验[J].中医杂志,2011,52(14):1187-1189.

[3] Hu XM, Liu F, Ma R. Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China[J]. Chinese Journal of Integrative Medicine,2010,16(4):368-477.

[4] 马俊丽,胡晓梅.含砷类中药治疗恶性血液病药代动力学及代谢机制研究进展[J].国际中医中药杂志,2012,34(1):80-82.

[5] 马俊丽,曲文闻,胡晓梅.砷制剂在骨髓增生异常综合征治疗中的应用[J].中华临床医师杂志,2012,6(16):149-150.

[6] 胡晓梅,唐旭东,麻柔,等.骨髓增生异常综合征发病机制的研究进展[J].国际输血及血液学杂志,2006,29(2):132-136.

[7] 胡晓梅,许勇钢,全日城,等.骨髓增生异常综合征T淋巴细胞异常与克隆造血[J].白血病·淋巴瘤,2011,20(1):71-75.

[8] 胡晓梅,马俊丽,麻柔.不同克隆类型骨髓增生异常综合征治疗方法的选择[J].白血病·淋巴瘤,2011,20(12):759-761.

[9] 胡晓梅,王洪志,毛翠,等.骨髓增生异常综合征克隆性异常8号染色体三体和7号染色体缺失的发生及临床意义[J].临床血液学杂志,2006, 19(6):340-343.

[10] 徐述,胡晓梅,许勇钢,等.青黄散加补肾健脾中药治疗骨髓增生异常综合症的临床观察[J].中国中西医结合杂志,2008,28(3):216-219.

[11] Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes[J]. Blood,2000,96(12):3671-3674.

[12] Shaffer LG, Tommerup N. An international system for human cytogenetic nomenclature (ISCN,2005)[M]. Basel:S. Karger Publishers,2005.

[13] Sole F, Espinet B, Sanz GF, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelody-splastic syndromes[J]. Br J Haematol,2000,108:346-356.

[14] 麻柔,胡晓梅.开展以遗传学类型分类骨髓增生异常综合征的针对性治疗研究[J].白血病·淋巴瘤,2010,19(5):262-263.

[15] Sun SZ, Ma R, Hu XM, et al. Karyotype and DNA-methylation responses in myelodysplastic syndromes following treatment with traditional Chinese formula containing arsenic[J]. Evidence- Based Complementary and Alternative Medicine,2012:969476.

相似文献/References:

[1]王一佼,刘锋.青黄散治疗骨髓增生异常/骨髓增殖性疾病病例报告[J].中国中医药信息杂志,2012,19(12):82.[doi:10.3969/j.issn.1005-5304.2012.12.035]
 [J].zhongguo zhongyiyao xinxi zazhi,2012,19(6):82.[doi:10.3969/j.issn.1005-5304.2012.12.035]
[2]周庆兵,胡晓梅,刘峰,等.骨髓增生异常综合征中医药研究进展[J].中国中医药信息杂志,2012,19(4):101.[doi:10.3969/j.issn.1005-5304.2012.04.050]
[3]宋敏敏,王月,方苏,等.胡晓梅温阳化毒治疗骨髓增生异常综合征经验[J].中国中医药信息杂志,2014,21(8):109.[doi:10.3969/j.issn.1005-5304.2014.08.035]
 [J].zhongguo zhongyiyao xinxi zazhi,2014,21(6):109.[doi:10.3969/j.issn.1005-5304.2014.08.035]
[4]邓中阳,方苏,王洪志,等.含砷中药复方青黄散安全有效治疗骨髓增生异常综合征方法研究[J].中国中医药信息杂志,2017,24(10):22.[doi:10.3969/j.issn.1005-5304.2017.10.006]
 DENG Zhong-yang,FANG Su,WANG Hong-zhi,et al.Study on Safe and Effective Clinical Methods for Arsenic-containing Compound Qinghuang Powder in Treatment of Myelodysplastic Syndrome[J].zhongguo zhongyiyao xinxi zazhi,2017,24(6):22.[doi:10.3969/j.issn.1005-5304.2017.10.006]
[5]瞿玮颖,邱仲川,陈珮,等.复方参鹿颗粒干预钙结合蛋白S100A8/A9改善较低危骨髓增生异常综合征患者无效造血机制研究[J].中国中医药信息杂志,2019,26(9):20.[doi:10.3969/j.issn.1005-5304.2019.09.006]
 QU Weiying,QIU Zhongchuan,CHEN Pei,et al.Study on Mechanism of Intervention of Compound Shenlu Granules in S100A8/A9 for Improving Ineffective Hematopoiesis in Patients with Lower-risk Myelodysplastic Syndrome[J].zhongguo zhongyiyao xinxi zazhi,2019,26(6):20.[doi:10.3969/j.issn.1005-5304.2019.09.006]

备注/Memo

国家自然科学基金(30973903)

更新日期/Last Update: